Skip to main content
italianoIT
European Commission logo print header

Impact of exposome on the course of lung diseases

Descrizione del progetto

DEENESFRITPL

Rivelare l’impatto dei fattori ambientali sulle malattie polmonari debilitanti

Il concetto di esposoma riflette la misura cumulativa delle influenze ambientali e delle risposte biologiche associate dal periodo perinatale in poi, comprese le esposizioni provenienti da ambiente, dieta, comportamento e processi endogeni. La sua importanza per la salute e le malattie è innegabile, in particolare per le malattie respiratorie croniche, in quanto risultano essere le principali cause di morti legati all’ambiente. Le malattie polmonari ostruttive croniche e la fibrosi cistica sono due malattie respiratorie croniche altamente debilitanti che condividono caratteristiche comuni, ma presentano origini opposte: la prima sembra essere strettamente correlata all’esposoma, mentre la seconda no. Per affrontare l’impatto dell’esposoma sul decorso di queste due malattie, il progetto REMEDIA, finanziato dall’UE, sta sviluppando approcci che combinano la raccolta di dati dell’esposoma e dati clinici, l’apprendimento automatico avanzato, l’uso di camere di simulazione atmosferica e lo sviluppo di singoli sensori. Tale approccio potrebbe indicare la via per una prevenzione e un trattamento efficaci.

Obiettivo

Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) are two very debilitating non-communicable diseases that are of particular interest to consider in parallel in a human exposome study. Their roots are opposite: COPD is currently considered to be mainly related to the external exposome, while factors outside of the exposome play a major role in CF. However, COPD and CF share common characteristics such as high phenotypic variability of unknown origin, which prevents good therapeutic efficacy. It is therefore clear that the overall picture must be supplemented by taking into account additional components of the exposome than those currently considered in COPD and CF. Thus, the overall objective of the REMEDIA project is to extend the understanding of the contribution of the exposome, taken as a complex set of different components, to COPD and CF diseases. We will exploit data from existing cohorts and population registries in order to create a unified global database gathering phenotype and exposome information; we will develop a flexible individual sensor device combining environmental and biomarker toolkits; and use a versatile atmospheric simulation chamber to simulate the health effects of complex exposomes. We will use machine learning supervised analyses and causal inference models to identify relevant risk factors; and econometric and cost-effectiveness models to assess the costs, performance and cost-effectiveness of a selection of prevention strategies. The results will be used to develop guidelines to better predict disease risks and constitute the elements of the REMEDIA toolbox (global unified database, sensor device, versatile atmospheric simulation chamber, machine learning supervised analyses, causal inference model, Pan-European multi-criteria risk assessment tool, econometric models, cost-effectiveness models, new guidelines and recommendations). Deciphering the impact of environmental components throughout life on the phenotypic variability of COPD and CF could represent a major breakthrough in reducing morbidity and mortality associated with these two non-curable diseases and would lead to the identification of modifiable risk factors on which preventive action could be implemented. REMEDIA will be part of the European Human Exposome Network established between the 9 projects funded within the Human Exposome programme call H2020-SC1-BHC-2018-2020.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-SC1-BHC-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2019-Single-Stage-RTD

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contribution nette de l'UE
€ 2 978 756,25
Indirizzo
Rue de tolbiac 101
75654 Paris
Francia

Mostra sulla mappa
Regione
Ile-de-France Ile-de-France Paris
Collegamenti
Altri finanziamenti
€ 0,00

Partecipanti (16)

Condividi questa pagina

Scarica

Data della firma CE 6 Dicembre 2019
Ultimo aggiornamento: 17 Luglio 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/874753/it

European Union, 2023